Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline’s Advair reduces exacerbations in COPD patients
The randomized study of 797 patients was a replicate study which found that after a year of treatment, patients treated with Advair Diskus 250/50 had a 30% reduction
The randomized study of 797 patients was a replicate study which found that after a year of treatment, patients treated with Advair Diskus 250/50 had a 30% reduction
Bill Forbes, vice president of R&D and chief development officer of Salix, said: “Salix will work diligently with the FDA over the next several days to compile a
The study will be a single center, Phase I safety and efficacy study of a single intravenous injection of PulmoBind in human subjects with no history of lung
The international, Phase III, randomized trial evaluated efficacy and safety of Nexavar versus placebo in 226 Asian patients with advanced hepatocellular carcinoma (HCC) who had not received prior
The 12-week, double-blind, placebo-controlled clinical trial involving 422 randomized patients compared PHX1149 in once-daily oral doses of 200mg and 400mg to placebo. Patients were allowed to continue selected
The new assay uses the biological specificity of ‘DNA methylation’ in prostate cancer, detecting the methylation of the gene GST-Pi. Methylation is a modification of DNA that occurs
Data from the two separate erosive esophagitis (EE) healing studies demonstrated that patients treated with TAK-390MR 60mg and 90mg experienced higher overall healing after eight weeks compared to
The company has said that the Latin American operation is expected to grow rapidly under the guidance of Mr Podesta and will be primarily focused on supporting the
Aridol is indicated for measuring airway hyperresponsiveness and has been approved in 14 European countries under the mutual recognition procedure (MRP). The necessary national approvals that follow the
The efficacy of Welchol compared to placebo was evaluated in patients receiving metformin-based or sulfonylurea-based therapy (either monotherapy or in combination with other antidiabetes therapy) in two separate